Home
About
Directors and Management
Careers
Corporate Governance
Board Charter
Code of Conduct
Audit Committee Charter
Nomination and Remuneration Committee Charter
Continuous Disclosure Policy
Share Trading Policy
Risk Management Policy
Social Media Policy
Performance Evaluation Process
Corporate Code of Conduct
Investors
Public Disclosure Policy
ASX Announcements
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Cellmid in the media
Top 20 Shareholders
Newsletter Archive
Contact
Shop évolis®
It’s rare for a company to own a whole new target this big
Home
It’s rare for a company to own a whole new target this big
Australian Life Sciences
November 25, 2019
First-in-Class mAb Oncology Program Will Rerate the Stock; Lots of Room to Grow for Advangen; New Target Price of 8.4c
November 25, 2019
Published by
Tiffany McMillan
on
November 25, 2019
Categories
Tags
Share
0
Tiffany McMillan
Shop évolis®
F
